by 
The epidermolysis bullosa market comprises products that are used in the treatment of epidermolysis bullosa (EB) disorder. EB is a rare, genetic skin disorder that causes fragile skin that blisters easily in response to minor injuries or friction. Therapies that are used for EB treatment include medication, supportive wound care, topical antibacterial medication, bandages, and genetic treatments. The global epidermolysis bullosa market is estimated to be valued at US$ 3,429.30 Mn in 2024 and is expected to exhibit a CAGR of 11.% over the forecast period from 2023 to 2030.
EB causes painful blisters to form in the skin and mucous membranes in response to natural friction from everyday activities like rubbing or scratching. Available treatments only focus on relieving symptoms and improving wound healing. The development of advanced gene therapies offers hope of eventually curing different subtypes of EB by addressing the underlying genetic defects. Growing research examining the potential of gene therapy, stem cell therapy, and other emerging biological treatment options are fueling market growth.
Key Takeaways
Key players operating in the epidermolysis bullosa market are Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim/Shionogi, and Phoenix Tissue Repair. These companies are developing new drug formulations and cell and gene therapies to treat various EB subtypes more effectively.
The growing awareness and clinical incidence of EB cases is driving increased demand for treatment options. Currently available medications only help manage symptoms but do not cure the disease. This unmet need is encouraging researchers to develop novel therapies.
Additionally, companies are expanding their global footprint through partnerships and clinical trials to commercialize new drugs and make them accessible to more patients worldwide. Investments are rising to accelerate drug development and bring more treatment options to market over the coming years.
Market Key Trends
One of the key trends gaining traction in the epidermolysis bullosa market is the growth of gene therapy as a treatment approach. Various gene therapy techniques are being evaluated that aim to deliver corrected genes to stem cells or target tissues. Companies are conducting trials for viral and non-viral gene therapies that show promise in restoring structural proteins like collagen and laminin. Advancements in vector engineering and targeted delivery methods could enable more effective gene therapies to emerge for curing EB in the long run.
Porter’s Analysis
Threat of new entrants: Low barriers preventing new entrants as significant investment required for R&D and clinical trials.
Bargaining power of buyers: Moderate bargaining power due to availability of substitutes and dependence on new treatment options.
Bargaining power of suppliers: High bargaining power as suppliers have specific expertise, infrastructure and research capabilities.
Threat of new substitutes: Low threat as EB is a rare genetic disorder without effective cure currently.
Competitive rivalry: High as major players focus on developing safe and efficacious treatment options.
Geographical Regions
North America dominates the market currently due to increased awareness levels, availability of advanced healthcare infrastructure, and presence of key market players.
Asia Pacific region is expected to grow at the fastest rate during the forecast period attributed to rising healthcare expenditure, increasing research funding, and growing patient population.
Geographical Regions
Currently, North America holds the largest share of the epidermolysis bullosa market due to growing awareness levels about rare diseases, rising research funding, and presence of advanced healthcare infrastructure.
The Asia Pacific region is poised to witness the highest CAGR over the forecast period 2023-2030. This is attributed to factors such as increasing healthcare expenditure, rising government support for rare disease research, growing patient population, and availability of low-cost treatment options.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
